Back

Daiwa maintains Buy on Sino Biopharmaceutical, estimates $355 million licensing revenue

Verifying
  • Sino Biopharmaceutical management reaffirmed double-digit annual revenue growth guidance.
  • $355 million in licensing revenue is expected for the full year.
  • Daiwa expects AstraZeneca and Cipla payments to be recognized in the second half.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.